Why the study?
Does cholestyramine treatment reverse the decreased platelet sensitivity to adenosine in patients with familial hypercholesterolaemia?
Does cholestyramine treatment reverse the decreased platelet sensitivity to adenosine in patients with familial hypercholesterolaemia?
Cholestyramine treatment reverses the defect in platelet A2 adenosine receptor coupling to adenylyl cyclase seen in patients with familial hypercholesterolaemia.
Answers are grounded in this paper and cite their sources.
Cholestyramine was associated with normalized platelet adenosine responsiveness in FH; leaves open causal confirmation and outcome impact in prospective trials.
Platelet-rich plasma was obtained from patients with untreated heterozygous familial hypercholesterolaemia (FH), from FH patients treated with cholestyramine and from control subjects. Responsiveness of platelets to the aggregation inhibitors adenosine, its analogue N-ethylcarboxamidoadenosine (NECA) and prostaglandin I2 was decreased in FH. Patients on cholestyramine therapy showed normal responsiveness to adenosine and NECA. There were only minor changes in the binding of [3H]NECA to high-affinity binding sites on platelet membranes from untreated FH or cholestyramine-treated FH patients. The initial rate of cyclic AMP formation in response to a high concentration of NECA was severely decreased in platelets from FH patients. By contrast, the rate of cyclic AMP formation in response to forskolin or a high concentration of prostaglandin I2 was unchanged. These data point to a defect in the coupling of the platelet A2 adenosine receptor to adenylyl cyclase in untreated FH patients.
No takes yet. Share an insight, caveat, or question.
Gasser et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: